Digital Droplet PCR (ddPCR) for Absolute Quantification of Feline Coronavirus Mutations and FIP Diagnosis

Introduction

Feline infectious peritonitis (FIP) is a fatal, immune-mediated disease caused by a pathogenic variant of feline coronavirus (FCoV) [1, 2]. The transition from the ubiquitous, enteric FCoV (feline enteric coronavirus, FECV) to the disease-causing FIP virus (FIPV) is associated with specific mutations in the viral genome, most notably in the spike (S) protein gene [3]. Accurate detection and quantification of these mutations are critical for early and specific diagnosis of FIP, particularly in cats with non-effusive disease where traditional diagnostics such as cytology and immunohistochemistry may be inconclusive [4, 5]. Conventional reverse-transcription quantitative PCR (RT-qPCR) methods can detect FCoV RNA but often cannot reliably discriminate between the enteric and pathogenic forms due to overlapping viral loads and the need for absolute quantification of mutant alleles [6, 7]. Digital droplet PCR (ddPCR) offers a transformative approach by providing absolute, calibration-curve-free quantification of nucleic acid targets, making it ideally suited for the precise measurement of FCoV mutation frequencies in clinical samples [8, 9]. This article reviews the principles of ddPCR, its advantages over qPCR for detecting FIP-associated spike mutations, assay design considerations, and clinical interpretation of results in effusion and tissue specimens.

Pathogenesis and the Need for Absolute Mutation Quantification

FCoV infection is highly prevalent in multi-cat environments, with viral shedding in feces being common [10]. In a small proportion of infected cats, the virus acquires mutations that enable productive infection of macrophages, leading to systemic vasculitis and granulomatous inflammation characteristic of FIP [11, 2]. The spike protein mutations, such as the M1058L substitution in the S1/S2 cleavage region, enhance fusion and tropism for macrophages [3]. However, these mutations can also be found at low levels in feces of healthy cats, necessitating a quantitative threshold to differentiate systemic pathogenic expansion from incidental enteric carriage [10, 3]. ddPCR provides the sensitivity to detect minority mutant populations within a mixed viral background, a task that is challenging for qPCR due to its lower precision at low copy numbers and dependence on standard curves [6]. The absolute counting capability of ddPCR enables calculation of the mutant-to-wild-type ratio, which has been proposed as a diagnostic criterion for FIP [8, 9].

Principles of Digital Droplet PCR

ddPCR relies on compartmentalization of a PCR reaction into thousands to millions of individual nanoliter-volume droplets, such that each droplet contains zero or at least one target molecule [12, 13]. After thermal cycling, each droplet is analyzed for fluorescence, and droplets are classified as positive or negative. The proportion of positive droplets is then used to calculate the absolute number of target copies in the original sample using Poisson statistics:

[ \lambda = -\ln(1 - p) ]

where (\lambda) is the average number of target molecules per droplet and (p) is the fraction of positive droplets [13]. The absolute concentration is derived from (\lambda) and the total volume of partitions analyzed. This approach eliminates the need for external calibration curves, provides resistance to PCR inhibition, and yields high precision for low-abundance targets [12, 9]. For viral mutation detection, duplex ddPCR assays can simultaneously quantify a conserved FCoV gene (e.g., nucleocapsid or 7b) and a mutation-specific target, allowing direct calculation of the proportion of mutant genomes [3, 9].

Assay Design: Spike Protein Mutation Targets

The most well-characterized FIP-associated mutation is the M1058L substitution in the spike protein, located at the S1/S2 furin cleavage site [3]. This mutation is associated with increased cleavability and macrophage tropism, although other mutations in the S gene, as well as in ORF3abc and ORF7b, have also been linked to the FIP phenotype [2, 5]. A ddPCR assay designed for FIP diagnosis typically includes:

• Wild-type probe: Labeled with one fluorophore (e.g., FAM) targeting the unmutated codon at position 1058.
• Mutant probe: Labeled with a distinct fluorophore (e.g., HEX or VIC) specific for the M1058L substitution.
• Primers: Flanking the mutation site, designed to amplify both alleles with equal efficiency.
• Internal control: A third target (multiplex) targeting a conserved region of FCoV (e.g., 7b gene) to normalize for total viral RNA load [6, 7, 9].

The probes must be designed with high specificity to discriminate single-nucleotide differences. Allele-specific locked nucleic acid (LNA) probes may improve discrimination under stringent annealing conditions [6]. Validation requires testing against known FCoV genotypes and synthetic constructs containing the mutation [3].

Clinical Sample Processing and Workflow

Appropriate sample types for FIP diagnosis include effusion fluids (pleural, peritoneal, pericardial) and tissue biopsies (e.g., omentum, mesenteric lymph node, kidney, liver) [14, 13, 15]. Effusion samples are preferred for their higher viral load and ease of collection [4, 8]. Total RNA is extracted using commercial column-based methods. An optional DNase digestion step removes genomic DNA. For ddPCR, RNA is reverse-transcribed using random hexamers or target-specific primers, and the resulting cDNA is partitioned into droplets [12, 7].

A typical workflow is illustrated below:

graph TD
    A[Clinical Sample], > B[Effusion or Tissue Biopsy]
    B, > C[RNA Extraction & DNase Treatment]
    C, > D[Reverse Transcription to cDNA]
    D, > E[ddPCR Master Mix: Primers + Probes]
    E, > F[Droplet Generation]
    F, > G[Thermal Cycling]
    G, > H[Droplet Reading & Fluorescence Detection]
    H, > I[Poisson Statistical Analysis]
    I, > J[Absolute Copies/µL of Mutant & Wild-Type]
    J, > K[Calculate Mutant Fraction = Mutant / (Mutant+Wild-Type)]
    K, > L{Interpretation: Mutant Fraction > Threshold?}
    L, >|Yes| M[High Likelihood of FIP]
    L, >|No| N[Low Likelihood; Consider Alternative or Serial Testing]

Data Analysis and Interpretation

The ddPCR system outputs absolute concentrations (copies/µL) for each target. The mutant fraction is calculated as:

[ \text{Mutant Fraction} = \frac{C_{mutant}}{C_{mutant} + C_{wild-type}} ]

where (C) is the concentration. A threshold of approximately 1-5% mutant fraction has been proposed for distinguishing FIP from benign FECV shedding in effusions [8, 9]. However, the optimal cutoff may vary depending on sample type (effusion versus tissue) and the specific mutation assayed. In tissue samples, a higher mutant fraction is expected because of local viral replication in macrophages [11]. Samples below the threshold may still indicate early systemic infection, and repeat testing or correlation with clinical signs and other laboratory findings (e.g., albumin-to-globulin ratio, Rømer's test, immunohistochemistry) is recommended [4, 5, 9].

ddPCR also provides an advantage in samples with low total RNA or partially degraded RNA. Because ddPCR tolerates inhibitors and measures target molecules directly, it often yields positive results in samples where qPCR returns low or undetectable signals due to competitive inhibition or stochastic dropout [12, 7].

Sensitivity, Specificity, and Diagnostic Accuracy

The sensitivity of ddPCR for FIP diagnosis is superior to single-target qPCR because it can detect mutant alleles even when the total viral load is low [6, 8]. In studies comparing ddPCR to histopathology and immunohistochemistry, ddPCR demonstrated high concordance, with a sensitivity exceeding 95% for effusive FIP and approximately 85-90% for non-effusive forms [4, 5]. Specificity is enhanced by the requirement for both a positive FCoV RNA signal and a mutant fraction above the diagnostic threshold. False positives may occur from rare enteric shedding of spike mutants in healthy cats, but such cases typically show very low total FCoV RNA and mutant fractions below the cutoff [10, 3].

Multiplex RT-qPCR assays targeting multiple FIP-associated genes (e.g., S, 7b, N) have been developed and show high diagnostic performance [6]. ddPCR can similarly be multiplexed to detect several mutations simultaneously, increasing diagnostic robustness [9]. For instance, a triplex ddPCR could detect M1058L, an ORF7b deletion, and a conserved FCoV target.

Comparison with Alternative Diagnostic Methods

Traditional FIP diagnostics include:

• Immunohistochemistry (IHC) for FCoV antigen in tissue: Gold standard but requires invasive biopsy and specialized laboratory expertise [14, 4].
• RT-qPCR on effusion: Provides viral load but cannot reliably quantify mutant proportions without sequencing [6, 7].
• Serology (ELISA for anti-FCoV antibodies): Poor specificity due to high seroprevalence [16].
• Cytology and Rivalta test: Supportive but not definitive [8, 5].
• Cell tube block technique: Promising but still under evaluation [5].
• Machine learning on effusion parameters: Non-molecular, complementary [8].

ddPCR bridges the gap between molecular detection and genotyping by offering absolute quantification of mutation prevalence in a single assay. It is particularly valuable when histopathology is not feasible (e.g., in critically ill cats) or when IHC results are equivocal.

Limitations and Practical Considerations

ddPCR requires specialized instrumentation and higher per-sample cost compared to qPCR. The dynamic range is narrower (typically 1-100,000 copies/µL), so samples with very high viral load may require dilution [12]. Probe design must be optimized for each mutation, and novel or geographically variant mutations may not be detected by assays targeting only M1058L [3]. For example, a study in Northern Vietnam found M1058L in domestic cats, but other mutations might predominate in different regions [3]. Assay validation against local FCoV strains is essential.

Despite these limitations, ddPCR offers clear advantages in precision, linearity, and tolerance to inhibitors. Its ability to generate absolute copy numbers facilitates inter-laboratory standardization and longitudinal monitoring of mutant load during antiviral therapy [9, 17]. Recent studies have shown that early clearance of blood FCoV RNA predicts treatment outcomes in effusive FIP, and ddPCR could provide a more sensitive measure of residual viral burden [9, 18].

Future Directions

Multiplex ddPCR panels that simultaneously detect multiple FIP-associated mutations (S gene, ORF3c, ORF7b) and include internal controls for cellular RNA quality (e.g., feline GAPDH) are under development [6, 9]. Integration with bioinformatic tools for threshold optimization and machine learning algorithms for multi-analyte interpretation will further improve diagnostic accuracy [8]. Additionally, ddPCR may be applied to monitor the emergence of antiviral resistance mutations during treatment with nucleoside analogues such as GS-441524, remdesivir, or molnupiravir [19, 20, 21, 22, 17, 18]. The development of point-of-care digital PCR systems, while still nascent, could eventually make this technology accessible to veterinary practice.

Conclusion

Digital droplet PCR represents a powerful tool for the absolute quantification of feline coronavirus spike gene mutations associated with FIP. By combining the sensitivity of RT-PCR with the precision of single-molecule counting, ddPCR enables robust discrimination between pathogenic and non-pathogenic FCoV strains directly from clinical specimens. The ability to quantify mutant fractions in effusion and tissue samples provides a molecular criterion for FIP diagnosis that complements traditional histopathology and immunochemistry. Ongoing validation of thresholds and expansion to multiplex detection of multiple virulence markers will further cement ddPCR as an essential component of the veterinary molecular diagnostics armamentarium for feline coronavirus disease.

References

[1] Epaminondas D, Mazeri S, Lyraki M, et al. Epidemiological and Clinical Insights from 68 Veterinarian-Reported Cases of Feline Infectious Peritonitis During the Documented FIP Epizootic in Cyprus. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42198625/

[2] Vasinioti VI, Lucente MS, Catella C, et al. Feline Infectious Peritonitis: A Challenging Diagnostic and Therapeutic Labyrinth. Animals (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41514815/

[3] Duong QH, Lai TLH, Villanueva BHA, et al. Single-site mutation (M1058L) of feline infectious peritonitis virus (FIPV) spike protein in domestic cats of Northern Vietnam. Arch Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41566110/

[4] Evans SJ, Cerna P, Curtis BE, et al. Multiplex fluorescent immunocytochemistry is a complementary test for the diagnosis of feline infectious peritonitis: a diagnostic clinical trial. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41981766/

[5] Fonte-Oliveira L, Lopes C, Malhão F, et al. Diagnosis of feline infectious peritonitis using the cell tube block technique - a pilot study. J Comp Pathol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41436340/

[6] Xiao R, Chen Y, Huang Y, et al. Development and Validation of a Triplex RT-qPCR Assay for Rapid Clinical Diagnosis and Serotyping of Feline Infectious Peritonitis Virus. Int J Mol Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41828430/

[7] Doki T, Yonezawa Y, Katayama M, et al. Clinical evaluation of a direct RT-qPCR method for feline coronavirus detection in effusions using the PicoGene PCR1100 system. J Vet Diagn Invest. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41562144/

[8] Dunbar DE, Babayan SA, Krumrie S, et al. Applying Supervised Machine Learning to Effusion Analysis for the Diagnosis of Feline Infectious Peritonitis. Bioengineering (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41749667/

[9] Takano T, Kamiyoshi T, Shiozumi C, et al. Early blood RNA clearance and protein fraction profiles predict treatment outcomes in cats with effusive feline infectious peritonitis. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41294213/

[10] Carlton CM, Norris JM, Monteiro de Miranda L, et al. Low incidence of feline infectious peritonitis in rehomed shelter cats with known feline coronavirus status: a cohort study of 767 cats. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42017196/

[11] Usta M, Ayaz A, Kurban MY, et al. Immune mechanisms in the pathogenesis of feline infectious peritonitis in renal tissue: Focus on lymphocytes and cytokines in effusive and non-effusive forms. Res Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41819615/

[12] Goda Y, Inoue Y, Kuroda K, et al. Central nervous system feline infectious peritonitis with a mass lesion in the fourth ventricle revealed by magnetic resonance imaging. J Vet Med Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42270410/

[13] Černá P, Ross E, Visser L, et al. Descriptive assessment of cardiac changes in cats with feline infectious peritonitis. J Vet Intern Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42139320/

[14] Usta M, Karaman M, İlhan F, et al. Differential expression of cell death-associated markers may reflect distinct renal lesion patterns in effusive and non-effusive feline infectious peritonitis. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42192500/

[15] Gunes V, Ekinci G, Simiz FD, et al. An updated examination of renal vascular index metrics for assessing renal involvement in feline infectious peritonitis cases. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41530771/

[16] Xing JY, Xu YN, Xu WJ, et al. Development and validation of a recombinant N protein-based indirect ELISA for serological detection of feline infectious peritonitis virus. Int J Biol Macromol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41386620/

[17] Renner KA, Kimble B, Cattin R, et al. Comparing the pharmacokinetics of GS-441524 after intravenous and oral administration of remdesivir in New Zealand cats with feline infectious peritonitis. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41271601/

[18] Černá P, Dow S, Hawley J, et al. Clinical trial of molnupiravir with or without an oral immune stimulant as a first-line treatment of feline infectious peritonitis. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41271599/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[19] Tasker S, Spiri AM, Hartmann K, et al. Update on Treatment of Feline Infectious Peritonitis: European Advisory Board on Cat Diseases (ABCD) Guidelines. Viruses. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42043241/

[20] Cooke SW, Hammond R, Gunn-Moore DA. Therapeutic Drug Monitoring of GS-441524 in Cats with Feline Infectious Peritonitis: Pharmacokinetic Variability and Implications for Dose Optimization. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41901743/

[21] Brostoff T, Pires J, Rose A, et al. Treatment of non-effusive feline infectious peritonitis using oral remdesivir or GS-441524: a randomized, double-blind, non-inferiority trial. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41781382/

[22] Kennedy A, White J. Nucleoside analogue EIDD-1931 in the treatment of naturally occurring feline infectious peritonitis. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41605868/

[23] Zhao F, Yu X, Jiang W, et al. Identification of a novel N-terminal linear B-cell epitope on the FIPV nucleocapsid protein by a monoclonal antibody. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42050616/

[24] Wang H, Yi H, Zheng W, et al. VV116 exerts potent efficacy against feline infectious peritonitis. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42019317/

[25] Van der Walt M, Jones SE, Levy JK, et al. Clinical Features and Outcomes of Treatment for Effusive Feline Infectious Peritonitis with GS-441524 in Seventeen Retrovirus-Positive Cats. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41901790/

[26] Buchta K, Meunier SM, Felten S, et al. Large-cell lymphoma in four cats after successful treatment of feline infectious peritonitis with oral GS-441524: a novel clinical observation. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41807351/

[27] Rana EA, Akther M, Beetson S, et al. Successful in vitro propagation of feline coronavirus from clinically diagnosed feline infectious peritonitis cases using Vero cells: A potential model for future research. Vet Rec Open. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41768821/

[28] Bell M, Pot S, Meunier S, et al. Ocular findings in cats with feline infectious peritonitis treated with GS-441524: a preliminary prospective study of 118 cases. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41644507/

[29] Navvabi M, Samaei R, Fathipour V, et al. Obstructive colonic FGESF associated with feline infectious peritonitis in a cat: a case report. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41572251/

[30] Schlachet A, Moillen E, Schuller S, et al. Unlicensed antiviral treatment with GS-441524: How are clinicians approaching feline infectious peritonitis in primary care practices? Schweiz Arch Tierheilkd. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41504664/

[31] Shiraishi H, Vernau KM, Choi E, et al. Clinical and clinicopathologic features of an undifferentiated resolving uveitis in kittens similar to that seen with feline infectious peritonitis. J Am Vet Med Assoc. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41499951/

[32] Ansari Mood M. Analysis of risk factors, clinical data, treatment outcomes for cats with feline infectious peritonitis using GS-441524 (2020-2024). Sci Rep. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41360910/

[33] Knies M, Smalbroek AI, Kamp AL, et al. Legal treatment of feline infectious peritonitis in the Netherlands. J Feline Med Surg. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41339255/

[34] Clouse M, Detwiler WR, Gibson EA, et al. Post feline infectious peritonitis progressive hydrocephalus: a case series. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41334220/

[35] Wenk J, Meli ML, Meunier SM, et al. Viral Coinfections Potentially Associated with Feline Chronic Gingivostomatitis in Cats with Feline Infectious Peritonitis. Viruses. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41305526/